The Hospital for Sick Children (SickKids)
The Hospital for Sick Children (SickKids)
Toronto, Ontario, Canada9 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS) | Epilepsies, Myoclonic, Epilepsy, Generalized, Epileptic Syndromes, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, brain disorder, central nervous system disorder, epilepsy, nervous system disorder, neurodevelopmental disorder, psychiatric disorder, visual epilepsy | Active, not recruiting | Phase 3 | 2026-09-17 | NCT06660394 | |
| A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE) | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Epileptic Syndromes, Lennox-Gastaut syndrome, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, brain disorder, central nervous system disorder, developmental and epileptic encephalopathy, epilepsy, hereditary disease, nervous system disorder, neurodevelopmental disorder, psychiatric disorder, visual epilepsy | Active, not recruiting | Phase 3 | 2026-09-15 | NCT06719141 | |
| A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction | Left Ventricular Systolic Dysfunction, Ventricular Dysfunction, Ventricular Dysfunction, Left, cardiovascular disorder, heart disorder, heart failure | Recruiting | Phase 3 | 2026-06-29 | NCT07192952 | |
| A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction | Left Ventricular Systolic Dysfunction, Ventricular Dysfunction, Ventricular Dysfunction, Left, cardiovascular disorder, heart disorder, heart failure | Recruiting | Phase 3 | 2026-06-15 | NCT07188805 | |
| CARE-ID: Dynamics of Respiratory Infections in Children and Transmission in Households and Schools | Bacterial Infections and Mycoses, COVID-19, Coronaviridae Infections, Infections, Mononegavirales infectious disease, Nidovirales infectious disease, Orthocoronavirinae infectious disease, Paramyxoviridae infectious disease, Pneumovirus Infections, RNA Virus Infections, bacterial infectious disease, bordetellosis, gram-negative bacterial infections, influenza, lung disorder, pertussis, pneumonia, respiratory syncytial virus infectious disease, respiratory system disorder, respiratory tract infectious disorder, viral infectious disease, viral pneumonia | Active, not recruiting | Not stated | 2026-05-01 | NCT06640387 | |
| Personalized Antisense Oligonucleotide for A Single Participant With PACS1 Gene Mutation Associated With Schuurs-Hoeijmakers Syndrome (SHMS) | Schuurs-Hoeijmakers syndrome | Not yet recruiting | Phase 1 / Phase 2 | 2026-03-16 | NCT07474298 | |
| Advancing Brain Outcomes in Pediatric Critically Ill Patients Sedated With Volatile AnEsthestic Agents | Pathologic Processes, Pathological Conditions, Signs and Symptoms, Respiration Disorders, Respiratory Aspiration, respiratory system disorder | Recruiting | Phase 3 | 2026-02-04 | NCT05867472 | |
| The Medtronic Harmony™ Transcatheter Pulmonary Valve Clinical Study | Cardiovascular Abnormalities, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, cardiovascular disorder, congenital heart disease, heart disorder, heart valve disorder, pulmonary valve insufficiency, tetralogy of fallot | Active, not recruiting | Not applicable | 2025-09-19 | NCT02979587 | |
| A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children | neoplasm | Active, not recruiting | Phase 1 / Phase 2 | 2025-06-22 | NCT02637687 |